SANF Share Price

Open 80.25 Change Price %
High 80.25 1 Day -0.70 -0.87
Low 79.55 1 Week -1.40 -1.73
Close 79.75 1 Month 6.00 8.14
Volume 760 1 Year 11.35 16.59
52 Week High 82.30
52 Week Low 65.00
SANF Important Levels
Resistance 2 80.40
Resistance 1 80.13
Pivot 79.85
Support 1 79.37
Support 2 79.10
BIT Italy Most Active Stocks
SPM 0.42 -6.67%
SPM 0.42 -6.67%
ISP 2.07 -2.36%
PMI 0.36 0.00%
PMI 0.36 0.00%
TIT 0.76 -1.30%
ENEL 4.02 1.26%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
EEMS 0.14 16.67%
TAS 4.07 12.74%
TAS 4.07 12.74%
TAS 4.07 12.74%
POPR 0.32 6.67%
VRW 1.13 6.60%
BIT Italy Top Losers Stocks
PRS 0.09 -10.00%
PRS 0.09 -10.00%
PRS 0.09 -10.00%
PRS 0.09 -10.00%
SPMR 5.41 -9.83%
MCH 0.67 -6.94%
MCH 0.67 -6.94%
MCH 0.67 -6.94%
SPM 0.42 -6.67%
SPM 0.42 -6.67%

Sanofi (BIT: SANF)

SANF Technical Analysis 4
As on 24th Feb 2017 SANF Share Price closed @ 79.75 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 73.43 & Buy for SHORT-TERM with Stoploss of 77.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
SANF Target for February
1st Target up-side 77.2
2nd Target up-side 79.09
3rd Target up-side 80.98
1st Target down-side 71.8
2nd Target down-side 69.91
3rd Target down-side 68.02
SANF Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website
SANF Address
54, Rue La Bo
Paris, 75008
Phone: 33 1 53 77 40 00
SANF Latest News
Lawmakers decry Army's planned Zika vaccine license to Sanofi   FiercePharma   - 24th Feb 17
Sanofi Backtracked on Actelion Offer Price Amid J&J Talks   Bloomberg   - 16th Feb 17
Sanofi Sells 5 Over-the-Counter Drugs for $88M (SNY)   Investopedia   - 13th Feb 17
A Heart-Stopping Patent Injunction Stay For Sanofi   Forbes   - 09th Feb 17
Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now   - 09th Feb 17
Sanofi (SNY) Q4 2016 Results - Earnings Call Transcript   Seeking Alpha   - 09th Feb 17
Sanofi Q4: Guidance Not Reassuring   Seeking Alpha   - 08th Feb 17
Sanofi 4Q net profit more than doubles   MarketWatch   - 08th Feb 17
Sanofi Genzyme head weighs in on drug price debate   Boston Business Journal   - 02nd Feb 17
Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice ...   GlobeNewswire (press release)   - 30th Jan 17
Interactive Technical Analysis Chart Sanofi ( SANF BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Sanofi
SANF Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.